NCT02269605View on ClinicalTrials.gov

Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

December 31, 2015

Conditions
HIV Infection
Interventions
OTHER

Placebo

Group 1: Placebo (sodium chloride 0.8 %) at single dose

DRUG

Bryostatin 1 (10ug/m2)

Group 2: Bryostatin 1 (10ug/m2) at single dose

DRUG

Bryostatin 1 (20ug/m2)

Group 3: Bryostatin 1 (20ug/m2) at single dose

Trial Locations (1)

28034

Infectious Diseases Service, Madrid

All Listed Sponsors
lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment | Biotech Hunter | Biotech Hunter